Results 1 to 10 of about 25,818 (186)
Interaction between crizotinib and tropifexor through in vitro and in vivo studies [PDF]
PeerJIn the context of cancer treatment, the employment of multiple drug therapies frequently results in a high prevalence of drug-drug interaction (DDI) in clinical practice.
An Shen +5 more
doaj +3 more sources
Current Oncology, 2022 The use, safety and effectiveness of crizotinib as part of the management of ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this retrospective review.
Amanda J. W. Gibson +8 more
doaj +1 more source
Frontiers in Oncology, 2022 Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients with
Woo Kyung Ryu +7 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Considerable attention has been raised on crizotinib- and sunitinib-induced hepatotoxicity, but the underlying mechanisms need further examination. In addition, limited therapeutic strategies exist to reduce the liver damage caused by crizotinib and ...
Lin Guo +5 more
doaj +1 more source
Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging
Pharmaceuticals, 2022 Crizotinib is a tyrosine kinase inhibitor approved for the treatment of non-small-cell lung cancer, but it is inefficient on brain metastases. Crizotinib is a substrate of the P-glycoprotein, and non-invasive nuclear imaging can be used to assess the ...
Malvika Sardana +14 more
doaj +1 more source
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. [PDF]
, 2016 The poor prognosis for patients with inflammatory breast cancer (IBC) compared to patients with other types of breast cancers emphasizes the need to better understand the molecular underpinnings of this disease with the goal of developing effective ...
Boerner, Julie +11 more
core +10 more sources
Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
Pharmaceuticals, 2021 Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients.
Joelle C. Boulos +8 more
doaj +1 more source
Precision oncology: the intention-to-treat analysis fallacy. [PDF]
, 2020 It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei +3 more
core +1 more source
Journal of Translational Medicine, 2022 Background The identification of early plasma biomarkers for clinical outcomes and drug resistance has key importance for risk stratification in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients.
Shasha Wang +7 more
doaj +1 more source
Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma [PDF]
Journal of Clinical and Diagnostic Research, 2016 The presence of an ALK (Anaplastic Lymphoma Kinase) rearrangement is a rare molecular feature in Non-Small Cell Lung Carcinoma (NSCLC), and concerns mainly non- or light smokers, young patients, with adenocarcinoma histological type.
Elodie Mussat +4 more
doaj +1 more source